Salts and Solid Forms of 4-hydroxy-N,N-diisopropyltryptamine

ChangeBridge: Patent Apps - Organic Chemistry (C07D)

Published December 3rd, 2025

Detected March 26th, 2026

Summary

The USPTO has published a patent application detailing new salts and solid forms of 4-hydroxy-N,N-diisopropyltryptamine (4-OH-DIPT), including hemi-glutarate and hemi-succinate forms. These forms are disclosed for their potential use in treating neurological and psychiatric disorders.

View original document View source feed page

What changed

This document is a USPTO patent application (US20260085041A1) for novel salts and solid forms of 4-hydroxy-N,N-diisopropyltryptamine (4-OH-DIPT), specifically hemi-glutarate and hemi-succinate variants. The application also covers methods for preparing and administering these compounds, highlighting their potential therapeutic applications in treating neurological diseases and psychiatric disorders.

As this is a patent application, it does not impose immediate compliance obligations on regulated entities. However, it signals potential future intellectual property protection and market exclusivity for these specific chemical entities and their uses. Companies involved in pharmaceutical research and development, particularly in the areas of neurology and psychiatry, should monitor this application's progress and consider its implications for their own research and development pipelines.

Source document (simplified)

← USPTO Patent Applications

SALTS AND SOLID FORMS OF 4-HYDROXY-N,N-DIISOPROPYLTRYPTAMINE HEMI-GLUTARATE AND HEMI-SUCCINATE

Application US20260085041A1 Kind: A1 Mar 26, 2026

Inventors

Samuel CLARK

Abstract

Disclosed herein are salts and solid forms of 4-hydroxy-N,N-diisopropyltryptamine hemi-glutarate (4-OH-DIPT), e.g., 4-OH-DIPT hemi-glutarate, 4-OH-DIPT hemi-succinate, 4-OH-DIPT hemi-succinate hydrochloride, and 4-OH-DIPT hemi-glutarate hydrochloride. The solid form may be a salt and/or a crystalline form of the 4-OH-DIPT, such as a polymorph of 4-OH-DIPT or a salt thereof. Also disclosed are methods for making the solid forms and methods for administering the solid forms. The disclosed solid forms of 4-OH-DIPT are useful for treating neurological disease and/or a psychiatric disorder in a subject.